Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential responses of APC-mutant CRCs to chemotherapy are not well understood. We report that expression of the transcription factor prospero homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. In genetic Apc-mutant mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically silent tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it promoted further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and immunostimulatory reprogramming of Prox1-deficient tumors, destroyed tumor fibrosis, and unleashed T cell-mediated killing of cancer cells. These results pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate a therapeutic strategy for chemoresistant and desmoplastic CRCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study targeting chemoresistant and desmoplastic colorectal cancer (CRC) cells by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin‐2 (ANGPT2) along with the cluster of differentiation 40 (CD40) agonistic antibodies destroyed tumor fibrosis and induced T cell‐mediated killing [7].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“We further analyzed genome-wide transcriptional responses of tumors to A2V+aCD40 treatment using gene set enrichment analysis (GSEA) (53).”
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“It is effective in highly mutated MSI CRCs, in which the T cell response has already been elicited (67, 68).”
Identification of stem cells in small intestine and colon by marker gene Lgr5
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., et al. (2007) · Nature · doi:10.1038/nature06196 · Cited by 5,687 · cited 1×
“…genes leucine-rich repeat–containing G protein– coupled receptor 5 ( Lgr5 ), lymphoid enhancer binding factor 1 ( Lef1 ), ring finger protein 43 ( Rnf43 ), and Eph receptor B2 ( EphB2 ) (34–36) was decreased but not completely abolished upon loss of expression in desmoplastic CMS4 CRCs (Figure 1C).”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 2×
“%) is characterized by low WNT signaling, a high proportion of stromal cells, prominent angiogenesis, and a poor prognosis (4).”
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · cited 11×
“We believe our results have broad implications for the development of novel therapies to treat APC -mutant MSS CRCs, which represent the majority of all CRC cases.”
InfluentialSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890 · cited 2×
“Enrichment was computed using single-sample GSEA (81).”
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491 · cited 1×
“To determine whether fibroblasts accelerate the progression of Prox1 -deficient tumors, we coimplanted AKP or AKPP organ-oids together with fluorescent intestinal fibroblasts isolated from mTmG + mice, in which all cells express the membrane-targeted tdTomato protein (41).”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“5-FU–based adjuvant chemotherapy is the standard of care for CRC and improves patient survival; however, a substantial proportion of the patients either do not respond to this treatment or relapse (2).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“Because CAF-mediated extracellular matrix (ECM) deposition and increased tumor stiffness promote tumor growth (42), we cultured organoids in synthetic hydrogels with a stiffness similar to that of either normal intestine (1.3 kPa) or CRC stroma (2.7 kPa), as described previously (43), in the…”
Influential
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“Another intriguing study in mouse colorectal cancer models showed that adaptive resistance to chemotherapy (5-FU and cisplatin) is associated with a pronounced stromal response and T-cell exclusion (291).”
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
“In a good example, blockade of VEGF alongside ANGPT2, when combined with CD40 agonistic antibodies, had an anti-angiogenic and immunostimulatory effect resulting in T-cell mediated killing of cancer cells in a colorectal tumor model [336].”
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Another study targeting chemoresistant and desmoplastic colorectal cancer (CRC) cells by targeting vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) along with the cluster of differentiation 40 (CD40) agonistic antibodies destroyed tumor fibrosis and induced T cell-mediated killing [7].”
BackgroundThe roles of tertiary lymphoid structures in chronic diseases
Sato, Y., Silina, K., van den Broek, M., Hirahara, K., & Yanagita, M. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00706-z · Cited by 320
“In a chemotherapy-resistant colorectal cancer model, the combination of antiangiogenic agents with agonistic anti-CD40 antibody induced vascular normalization, TLS development and T cell-mediated tumour control 125 .”
Metadata
- Authors
- Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., Lutolf, M. P., Perentes, J., Corse, E., Bianchi, R., Wetterwald, L., Kim, J., Oliver, G., Delorenzi, M., De Palma, M., & Petrova, T. V.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- École Polytechnique Fédérale de Lausanne (CH)
- University of Zurich (CH)
- F. Hoffmann-La Roche AG (CH)
- Northwestern University (US)
- Corresponding author
- Petrova, Tatiana V.
- ORCID
- Ragusa, Simone
- Prat-Luri, Borja
- González-Loyola, Alejandra
- Nassiri, Sina
- Squadrito, Mario Leonardo
- Guichard, Alan
- Cavin, Sabrina
- Gjorevski, Nikolce
- Barras, David
- Marra, Giancarlo
- Perentes, Jean
- Corse, Emily
- Bianchi, Roberta
- Wetterwald, Laureline
- Kim, Jaeryung
- Oliver, Guillermo
- Delorenzi, Mauro
- De Palma, Michele
- Petrova, Tatiana V.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1199-1216
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269598
- OpenAlex
- W3004730319
- Cited by
- 56
- References
- 82
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Swiss Cancer League (KLS 3406-02-2016, KFS-3759-08-2015)
- MEDIC Foundation (Not available)
- Fondation de lutte contre le cancer (N/A)
- Roche (N/A)
- Swiss Bridge Foundation (N/A)
- N/A (N/A)
- San Salvatore Foundation (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, desmoplasia, chemoresistance, Prox1, APC mutation, Wnt signaling, MMP-14, tumor stroma, angiopoietin-2, CD40 agonist, tumor fibrosis, T cell immunity, tumor angiogenesis
- MeSH terms
- Antineoplastic Agents, Immunological, Prospero-Related Homeobox 1 Protein, Animals, Cell Line, Humans, Immunotherapy, Neoplasms, Experimental, Neovascularization, Pathologic, Colorectal Neoplasms, Homeodomain Proteins, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Tumor Suppressor Proteins, Adenomatous Polyposis Coli Protein, Vascular Endothelial Growth Factor A, Angiopoietin-2, Mice, Matrix Metalloproteinase 14
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. https://app.cochat.ai/papers/10.1172/jci129558
- The paper
- Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., Lutolf, M. P., Perentes, J., Corse, E., Bianchi, R., Wetterwald, L., Kim, J., Oliver, G., Delorenzi, M., De Palma, M., & Petrova, T. V. (2020). Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci129558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.